. Author manuscript; available in PMC: 2016 Mar 16.

Published in final edited form as: Leukemia. 2015 Aug 20;30(2):325–330. doi: 10.1038/leu.2015.227

Table 3.

Treatments for Patients with Acute Leukemia and Myelodysplastic Syndrome

Treatment for AL/MDS	Percent of Patients
Treatment for AL/MDS	AL (n=38)	MDS (n=57)
HMA (azacitadine or decitabine)	8	28
Cytarabine-based	79	19
Allo-HSCT	11	5
Hyper-CVAD	8	0
IMID	3	11
FTI/TKI	3	9
Other	3	7
None	3	18

AL, acute leukemia; MDS, myelodysplastic syndrome; n, number; HSCT, hematopoietic stem cell transplant; hyper-CVAD, hyper-fractionated cyclophosphamide, adriamycin, vincristine, dexamethasone; IMID, immune-modulating agent (thalidomide or lenalidomide); FTI, farnesyl transferase inhibitor; TKI, tyrosine kinase inhibitor, HMA, hypomethylating agent